RANDOMIZED CONTROL TRIAL: MYCOPHENOLATE MOFETIL IN PATIENTS W/ IGA NEPHROPATHY

随机对照试验：霉酚酸吗替酯治疗 IGA 肾病患者

• 批准号: 7375426
• 负责人: ROBERT J WYATT
• 金额: $ 0.43万
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375426
• 关键词: RANDOMIZED; CONTROL; TRIAL; MYCOPHENOLATE; MOFETIL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This multicenter clinical trial tests the efficacy of Mycophenolate Mofetil in reducing proteinuria, which is usually equated with improvement in prognosis, in patients with IgA Nephropathy who are being maintained on a standard regimen of an angiotensin converting enzyme inhibitor and fish oil supplements.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项多中心临床试验测试了霉酚酸酯莫夫蒂尔在还原蛋白尿中的疗效，通常等于预后的改善，IGA肾病患者正在维持在血管紧张素抑制剂抑制剂和鱼油补充剂的标准方案中。